The price that Boston Scientific (Natick, Massachusetts) has paid for troubled cardiac rhythm management firm Guidant has far exceeded its 2006 winning bid of $27.2 billion. Plagued with product liability problems, Guidant has cost Boston Sci millions more to settle lawsuits related to electrical flaws in its implantable cardioverter defibrillators (ICDs). And now those troubles have led to alleged criminal violations of the Federal Food, Drug, and Cosmetic Act. Charges were filed yesterday by the Department of Justice (DOJ) in federal district court in St. Paul, Minnesota. (Medical Device Daily)